Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has earned an average recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $3.33.

SYRS has been the subject of several analyst reports. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a research note on Friday. They set a “sell” rating for the company. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th.

Syros Pharmaceuticals Stock Performance

SYRS stock opened at $0.21 on Monday. The firm has a fifty day moving average price of $0.23 and a 200 day moving average price of $1.95. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $7.96. The firm has a market cap of $5.67 million, a PE ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the company earned ($1.35) earnings per share. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In other news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC increased its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 298,575 shares of the company’s stock after buying an additional 139,400 shares during the period. Exome Asset Management LLC owned about 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent quarter. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.